The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 7, pp. 1128-1131. DOI 10.1345/aph.1C460
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nelson, L. A.
Right arrow Articles by Hausafus, S. N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nelson, L. A.
Right arrow Articles by Hausafus, S. N

DRUG INFORMATION ROUNDS

Melatonin for the Treatment of Tardive Dyskinesia

Leigh Anne Nelson, PharmD BCPP

at time of writing, Assistant Professor of Pharmacy Practice and Psychiatry, St. Louis College of Pharmacy/St. Louis University School of Medicine, St. Louis, MO; now, Medical Science Manager, Neuroscience, Bristol-Myers Squibb, Kansas City, MO

J Michael McGuire, PharmD BCPP

Assistant Professor of Pharmacy Practice and Psychiatry, St. Louis College of Pharmacy/St. Louis University School of Medicine

Sarah N Hausafus, BSPharm

at time of writing, PharmD Student, St. Louis College of Pharmacy; now, Pharmacist, Schnuck's Pharmacy, St. Louis, MO

Reprints: J Michael McGuire PharmD BCPP, St. Louis College of Pharmacy, 4588 Parkview Place, St. Louis, MO 63110-1088, FAX 314/446-8500, E-mail mmcguire{at}stlcop.edu

OBJECTIVE: To review the available literature regarding the use of melatonin in the treatment of tardive dyskinesia (TD).

DATA SOURCES: Literature was identified through MEDLINE (1966–September 2002), PsycINFO (1967–September 2002), and references of relevant articles. Review articles, case reports/series, and animal and human studies were reviewed.

DATA SYNTHESIS: Melatonin has been investigated in TD based on its antioxidant properties. Animal studies and several human case series describe an association between melatonin and TD. Two recent, controlled studies evaluated the role of melatonin in the treatment of TD.

CONCLUSIONS: There is a paucity of data evaluating the use of melatonin in TD. Both of the controlled studies evaluating its use are limited by methodologic issues. Although the most recent trial did report a statistically significant improvement in TD with melatonin, these results are not considered to be clinically significant. There are inadequate data at the present time to support the use of melatonin in patients with TD.

Key Words: melatonin, tardive dyskinesia

Published Online, June 5, 2003. www.theannals.com, DOI 10.1345/aph.1C460




homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.